But while the U.S. Food and Drug Administration has approved more than two dozen drugs targeting a range
of male
sexual matters, pharma has turned a cold shoulder to female
dysfunction, despite the prevalence
of conditions like hypoactive
sexual desire disorder, a chronic disinterest in sex estimated to affect 8 to 14
percent of American women ages 20 to 49.
Selective serotonin reuptake inhibitors (SSRIs) boost serotonin levels in people with depression, but between 20 and 70
percent of people who take them experience a range
of symptoms related to
sexual dysfunction.